Dr. Westin on the Role of R-CHOP in DLBCL

Video

In Partnership With:

Jason Westin, MD, MS, FACP, discusses the role of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.

Jason Westin, MD, MS, FACP, director, Lymphoma Clinical Research, section chief, Aggressive Lymphoma, and associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the role of rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma (DLBCL).

R-CHOP has been the standard treatment for patients with DLBCL for many years, says Westin.

Blood tests, CAT scans, and physical examinations can help determine whether a patient is likely to benefit from R-CHOP, says Westin. If a patient is not likely to respond to R-CHOP, alternative treatment options should be considered.

Treatment-related toxicities, such as nausea, fatigue, and neutropenic infections, are fairly common with R-CHOP, and are generally well managed, says Westin. As such, the majority of patients are able to complete the full 6 cycles of R-CHOP, concludes Westin.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD